2012-10-25 09:29:49 - This report provides a comprehensive overview of the US specialty pharmaceutical market covering various disease segments and the specialty pharmacy market. The specialty pharma realm is intensely competitive with numerous corporations holding the reins of the same. The leading industry players include Pfizer, Amgen, Roche, Eli Lilly, NovoNordisk and J&J. Also, market dynamics viz., key trends, industry developments, growth drivers and the challenges faced by the industry are discussed in detail.

With the advent of novel technologies, companies operating in the healthcare/pharmaceutical/therapeutic industry are now scaling new heights. Also, this industry is boosted by the rising number of incidences of health related issues emanating from the changing lifestyle and continuously evolving surrounding environment. To address the growing demand for better healthcare options and the unmet needs within the chronic disease segment, respective companies are coming up with new and improved therapies some of which fall within the bounds of specialty pharmaceuticals.
There is no particular definition for specialty pharmaceutical but on the basis of some parameters, it takes into account the following:


-Biotech origin of drugs/plasma derivatives
-Orphan drugs
-Skyrocketing cost of treatment
-Treatment for a chronic condition by specialist
-Patient monitoring and education

is required
-Distribution calls for special handling

The report consists of the following sections:-

1. Specialty Pharmaceuticals

1.1 Overview
1.2 Key Application Areas of Specialty Pharmaceuticals
1.3 Specialty Products Distribution
1.4 Specialty Pharmacy
1.5 Specialty Distribution

2. Specialty Pharmaceutical Market Size

2.1 The US Specialty Pharmaceutical Market

3. Market Dynamics

3.1 Key Trends
3.2 Industry Developments
3.3 Growth Drivers
3.4 Challenges

4. Competitive Landscape

5. Company Profiles

5.1 Amgen Inc.
5.2 Novo Nordisk
5.3 Pfizer Inc.
5.4 Roche
5.5 Johnson & Johnson
5.6 Eli Lilly and Company

6. Market Outlook

List of Charts

Oral Specialty Drugs Dispensed by Location
Injectable Specialty Drugs Dispensed by Location
Flow of Products within the Specialty Pharmacy Channel
SP Benefits Model
Specialty Distributor sales by Customer
Global Pharmaceutical Market (2003-2011)
The US Specialty Pharmaceutical Market Size (2011)
The US Plasma Derived FVIII Market Share by Companies
Biotechnology Drugs Currently in Development (2011)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Global Recombinant FVIII Market Revenues (2005-2011)
Global Recombinant FIX Market Size (2006-2011)
Causes of ESRD in the US (2011)
Worldwide Patients with End Stage Renal Disease (2005-2010)
Global Diabetic Population (2006-2011)
Number of Cancer Cases Worldwide (2007-2011)
Global Ageing Population (+60 years) (2005-2013F)
Global Healthcare Spending (2005-2015E)
Specialty Mail Pharmacy Market Share (2011)
Specialty Distributors Market Share (2011E)
Amgen’s Revenue Share by Business segment (2011)
Amgen’s Revenues and Net Income (2011)
Novo Nordisk Revenue Share by Business Segments (2011)
Novo Nordisk Revenues & Net Income (2008-2011)
Pfizer’s Revenue Share by Business Segments (2011)
Pfizer’s Revenues & Net Income (2008-2011)
Roche’s Revenue Share by Business Segments (2011)
Roche’s Revenues and Net Income (2007-2011)
Johnson & Johnson’s Revenue Share by Business Segments (2011)
Johnson & Johnson’s Revenues and Net Earnings (2008-2011)
Eli Lilly’s Revenues by Segment (2011)
Eli Lilly’s Revenue and Net Income (2008-2011)

List of Tables

Specialty Pharmaceuticals’ Key Application Areas
Novel Product Launches in Key Specialty Areas (2009-2011)
Key Players Providing Manufacturer Services
The US Specialty and Overall Market Size (2008-2011)
The US Specialty Pharmaceutical Market Constituents (2011)
Key Oncology Therapy Sales (2011)
Key Rheumatoid Arthritis Therapies’ Sales (2011)
Key HIV/AIDs Therapies’ Sales (2011)
Key Multiple Sclerosis Therapies’ Sales (2011)
Key Renal Therapies’ Sales (2011)
Key DVT Therapies’ Sales (2011)
Key Growth Hormone Therapies’ Sales (2011)
Key Hepatitis-C Therapies’ Sales (2011)
Key PAH Therapies’ Sales (2011)
Orphan Drug Sales (2011)
Specialty Pharmacy market (2010 & 2011)
Specialty Pharmacy Transactions (2005-2012)
Specialty Distribution Transactions (2007-2011)
Biosimilar Adoption Rates by Region and Drug Class
Biobetters
Specialty Drugs under Development
Selected Product Launches (2012-2016)
Projected Specialty Generic Launches (2012-2015)
Long Acting FIX & FVIII under Late-Stage Development
Extended Half Life rFVIII Agents
Extended Half Life rFIX Agents
Recombinant and Improved Formulations of Erythropoietin
Global Spending Outlook for Top 20 Therapy Area (2016E)
Expiry of Bio Drugs’ patents by company (2012-2019)
Major protection expiries by country (2012-2016)
Global Biologics Spending (2006-2016E)
Global Availability of NMEs (2011)
New Patient Registrations in Worldwide Bleeding Disorders Market (2008-2013E)
Patients Worldwide Waiting for Better Treatment Options (2011)
Leading 20 Specialty Drugs (2011)

For further details, kindly visit konceptanalytics.com/reportDetail.aspx?reportID=423